A. Chewing gum B. Administration of alvimopan C. NG tube placement D. Avoidance of opioid analgesia

A. 10% B. 20% C. 30% D. 70%

A. Local wound infiltration with bupivacaine liposome B. Use of intravenous acetaminophen C. Use of epidural analgesia D. Placing the patient on nothing-by-mouth status following the procedure

A. It is a practice employed by most colorectal surgeons in the United States B. Its use prior to left- and right-sided resections has not been endorsed by the Canadian Society of Colon and Rectal Surgeons C. It has been conclusively demonstrated to have only adverse effects on postoperative outcomes D. It has not been studied independently as part of an ERAS pathway

A. 12 B. 24 C. 48 D. 72

A. It is a practice that differs from AUA Best Practice Guidelines B. It reduces bleeding risk for patients with bladder cancer C. It is not part of ERAS protocols D. It is avoided by many robotic/laparoscopic specialists and urologic oncologists

A. They are a potentially fatal complication of the cystectomy procedure B. They have been associated with the use of prolonged antibiotic coverage C. Current infection rates are less than 2% D. They have been associated with chronic antacid therapy

A. It requires the use of a REMS B. It cannot be administered for more than 15 doses C. It has been shown to help improve GI recovery time following radical cystectomy D. Its use can be continued after hospital discharge

A. Adequate compensation for REMS-required services B. Use of EHR systems to exchange data C. Establishing direct communication strategies to health care providers and patients D. All of the above

A. 8% B. 18% C. 28% D. 48%